Next Article in Journal
Exercise for People with Cancer: A Systematic Review
Previous Article in Journal
Experiences of Canadian Oncologists with Difficult Patient Deaths and Coping Strategies Used
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours

1
Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
2
Southern Tohoku bnct Research Center, Koriyama, Japan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2017, 24(4), 285-289; https://doi.org/10.3747/co.24.3500
Submission received: 3 May 2017 / Revised: 7 June 2017 / Accepted: 10 July 2017 / Published: 1 August 2017

Abstract

Purpose: We evaluated the efficacy and toxicity of accelerated hypofractionated radiotherapy (AHYPOF-RT) for central-type small lung tumours. Methods: Between November 2006 and January 2015, 40 patients with central-type small lung tumours underwent AHYPOF-RT delivered using 10 MV X-rays and a coplanar 3-field technique. The number of fractions ranged from 24 to 28, with a fraction size of 2.5–3 Gy. A total dose of 69–75 Gy to the isocentre of the planning target volume was administered to each patient. Cumulative survival and local control rates were calculated using the Kaplan–Meier method. Results: The 27 men and 13 women enrolled in the study had a median age of 79 years (range: 60−87 years). The tumour stage was T1a in 9 patients, T1b in 17 patients, and T2a in 14 patients, with a median size of 26.5 cm (range: 11–49 cm). The median follow-up period was 23 months. A complete response was achieved in 3 patients (7.5%), and a partial response, in 17 patients (42.5%). The overall 2-year and 3-year local control rates were 87.3% and 81.8% respectively; the 2-year and 3-year overall survival rates were 78.9% and 66.7% respectively. Grade 3 pneumonitis occurred in 3 patients; no other severe adverse events (≥grade 3) were observed in any patient. Conclusions: Accelerated hypofractionated radiotherapy using a fraction size of 2.5–3 Gy was highly safe and can be a more effective treatment option than conventional radiotherapy for patients with central-type small lung tumours.
Keywords: lung tumours; central type; radiotherapy; accelerated hypofractionation lung tumours; central type; radiotherapy; accelerated hypofractionation

Share and Cite

MDPI and ACS Style

Hatayama, Y.; Aoki, M.; Kawaguchi, H.; Hirose, K.; Sato, M.; Akimoto, H.; Tanaka, M.; Fujioka, I.; Ichise, K.; Ono, S.; et al. Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours. Curr. Oncol. 2017, 24, 285-289. https://doi.org/10.3747/co.24.3500

AMA Style

Hatayama Y, Aoki M, Kawaguchi H, Hirose K, Sato M, Akimoto H, Tanaka M, Fujioka I, Ichise K, Ono S, et al. Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours. Current Oncology. 2017; 24(4):285-289. https://doi.org/10.3747/co.24.3500

Chicago/Turabian Style

Hatayama, Y., M. Aoki, H. Kawaguchi, K. Hirose, M. Sato, H. Akimoto, M. Tanaka, I. Fujioka, K. Ichise, S. Ono, and et al. 2017. "Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours" Current Oncology 24, no. 4: 285-289. https://doi.org/10.3747/co.24.3500

APA Style

Hatayama, Y., Aoki, M., Kawaguchi, H., Hirose, K., Sato, M., Akimoto, H., Tanaka, M., Fujioka, I., Ichise, K., Ono, S., & Takai, Y. (2017). Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours. Current Oncology, 24(4), 285-289. https://doi.org/10.3747/co.24.3500

Article Metrics

Back to TopTop